Healthcare Industry News: endoscopy
News Release - October 6, 2008
Given Imaging Launches RAPID(R) 5 Access SoftwareFacilitates Physicians Reading PillCam Videos Anywhere, Anytime
YOQNEAM, ISRAEL--(Healthcare Sales & Marketing Network)--Oct 6, 2008 -- Given Imaging Ltd. (GIVN ) today announced the launch of RAPID 5 Access, new software that facilitates physicians' reading PillCam videos anytime, anywhere with the most advanced software tools. This new software also enables network-based storage of PillCam studies and the import and export of patient data to and from electronic medical record systems.
"RAPID 5 Access goes one step further in making PillCam capsule endoscopy fit seamlessly into the workflow of a physician's office," said Homi Shamir, president and CEO of Given Imaging. "Integration into a facility's software system further reduces the amount of time spent on process and frees the physician and staff to spend more time caring for patients."
"Software advances, such as RAPID Access, leverage our existing IT infrastructure and allow us to more easily offer the gold standard of small bowel diagnosis, PillCam capsule endoscopy, while focusing more of our time on caring for patients," said Scott R. Ketover, MD, President & Chairman, Minnesota Gastroenterology. "RAPID Access was very easy to implement throughout our network of offices that offer capsule endoscopy services. With RAPID Access we are able to manage the data and files created by the capsule endoscopy system much more efficiently."
RAPID 5 Access brings many advantages to the Capsule endoscopy Program:
-- Utilizes existing computers and network system to create, manage and store PillCam studies
-- Imports patient demographic data for easy patient check-in
-- Exports procedure reports and images for use in electronic medical record systems
In addition, RAPID 5 Access makes available all of the latest capabilities and features offered by RAPID 5, the latest PillCam capsule endoscopy reading software.
About Given Imaging Ltd.
Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company's technology platform is the PillCam® Platform, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient, a sensor array, data recorder and RAPID® software. Given Imaging has a number of available capsules: the PillCam SB video capsule to visualize the entire small intestine which is currently marketed in the United States and in more than 60 other countries; the PillCam ESO video capsule to visualize the esophagus; the Agile(TM) patency capsule to determine the free passage of the PillCam capsule in the GI tract and the PillCam COLON video capsule to visualize the colon that has been cleared for marketing in the European Union. PillCam COLON has received a CE Mark, but is not cleared for marketing or available for commercial distribution in the USA. More than 750,000 patients worldwide have benefited from the PillCam capsule endoscopy procedure. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel. It has operating subsidiary companies in the United States, Germany, France, Japan, Australia and Singapore. Given Imaging's largest shareholders include Elron Electronic Industries (ELRN ) (Tel Aviv:ELRN.TA ). For more information, visit http://www.givenimaging.com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of significant litigation, (8) our ability to obtain reimbursement for our product from government and commercial payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, and (11) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2007. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
Source: Given Imaging
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.